Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aurinia Pharmaceuticals reports robust Q4 earnings and navigates growth challenges

Aurinia Pharmaceuticals had a strong Q4 performance, with revenue growth and patient access milestones. Despite challenges from COVID-19 and legal disputes, the company remains financially stable and focused on driving growth through patient-centric strategies. Opportunities lie in improving patient adherence and expanding market reach.

Aurinia Pharmaceuticals reports strong Q1 performance and eyes global expansion

Aurinia Pharmaceuticals delivered robust financial performance in Q1 2023, with strong revenue growth and positive patient outcomes.
The company's strategic initiatives and globalization efforts position it well for future growth and market expansion.
Challenges such as slowing new patient starts and persistency caution require focused attention for sustained success.
Opportunities lie in enhancing patient engagement, driving revenue through new patient starts, and strengthening competitive positioning.

Aurinia Pharmaceuticals excels in Q2 earnings, eyes growth opportunities

Aurinia Pharmaceuticals delivered strong financial results in Q2 2023, driven by revenue growth, improved commercial metrics, and effective cost management.
The company's focus on patient awareness, clinical differentiation, and market access for LUPKYNIS positions it well in the competitive landscape of lupus nephritis treatment.
While facing challenges such as seasonality impact and strategic uncertainties, Aurinia remains optimistic about its financial stability, pipeline progress, and growth opportunities.

Aurinia Pharmaceuticals reports strong Q3 performance and explores growth

Aurinia Pharmaceuticals demonstrated robust financial performance and strategic partnerships in Q3 2023, positioning itself for future growth.
While facing challenges in persistency rates and strategic decision-making, the company is leveraging upcoming guidelines and data submissions for market advantage.
Opportunities in education, regulatory approvals, and pricing strategies present avenues for sustained growth and market expansion in the lupus nephritis segment.

Aurinia Pharmaceuticals reports strong Q1 earnings and growth opportunities

Aurinia Pharmaceuticals delivered a robust performance in Q1 2024, driven by strong revenue growth and strategic cost management.
While facing challenges in managing expenses and optimizing patient outcomes, the company remains well-positioned for future profitability.
With a focus on expanding market access, enhancing treatment guidelines, and leveraging its financial strength, Aurinia is poised for continued growth and success.

Aurinia Pharmaceuticals reports robust Q2 revenue growth and strategic initiatives

Aurinia Pharmaceuticals delivered strong financial performance in Q2 2024, with notable revenue growth and operational efficiency.
While facing challenges in revenue guidance and market expectations, the company's strategic initiatives and product adoption present growth opportunities.
With a focus on product development, market expansion, and patient engagement, Aurinia is poised for continued success in the pharmaceutical industry.

Aurinia Pharmaceuticals reports robust Q3 earnings and strategic milestones

Aurinia Pharmaceuticals delivered impressive financial results in Q3 2024, showcasing growth in revenue and operational efficiency.
Despite undergoing a significant restructuring, the company remains focused on innovation, achieving milestones, and expanding its market presence.
With a strong cash position and strategic outlook, Aurinia is poised for continued success and growth in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets close. Aurinia's management team will also host a conference call at 5:00 p.m. EDT to discuss the Company's financial results and to provide a general business update. The conference call and webcast is scheduled for May 6, 2021 at 5:00 p.m. ET. In order to par

Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) was trending Tuesday afternoon possibly amid the stock making a new 52-week low. Below are the technical levels to watch on the chart.

Aurinia Pharmaceutical Stock Showing A Potential Reversal Pattern: 4 Key Levels To Watch

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET. In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate w

Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has presented additional efficacy data from the AURA-LV and AURORA 1 trials of Lupkynis (voclosporin) in lupus nephritis (LN). Aurinia shared the data at the National Kidney Foundation 2021 Spring Clinical Meeting.

Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in lupus nephritis (LN). The data were shared at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings by Anca D. Askanase, M.D., M.P.H., Founder and Director of Columbia University Irving Medical Center's Lupus Center and the Dire

Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings

AUPH stock still has to prove its Lupus drug can sell and its price and the competition make that an unclear proposition. The post Aurinia Stock Has Great Potential, but It's Not a Buy Right Now appeared first on InvestorPlace.

Aurinia Stock Has Great Potential, but It's Not a Buy Right Now

Aurinia saw its first product, Lupkynis, approved and launched in January, and analysts widely expect it to be a blockbuster. Despite completely removing regulatory risk from the picture, shares are essentially unmoved since before approval.

Aurinia Should Be A Long-Term Winner With Lupkynis Now On The Market

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS™ (voclosporin), based on an independent analysis issued by the Institute for Clinical and Economic Review (ICER) in a revised Evidence Report issued on March 12, 2021. The report finds that LUPKYNIS represents an important new treatment option for patients living

Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in multiple upcoming investor conferences including the: Cowen 41st Annual virtual Healthcare Conference fireside chat on Thursday, March 4, 2021 at 2:10 p.m. ET; H.C. Wainwright Global Life Sciences Conference fireside chat available on Tuesday, March 9, 2021 at 7:00 a.m. ET; and Oppenheimer's 31st Ann

Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences

Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2020 Results - Earnings Call Transcript

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars. “Over the past year, Aurinia matured into a fully-integrated biopharmaceutical company with capabilities spanning R&D, clinical, regulatory, CMC, and commercial. The recent FDA approval and immediate launch

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

Aurinia Pharmaceuticals (NASDAQ:AUPH) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.

Earnings Preview: Aurinia Pharmaceuticals

Aurinia (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Aurinia (AUPH) This Earnings Season?

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat at the (virtual) SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 1:00 p.m. ET. In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corpora

Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference

On January 22, the FDA approved Voclosporin to treat Lupus Nephritis. A label was included with a personal dosage protocol, which implies that VC will be protected against generics until 2037.

Aurinia Pharmaceuticals: A Great Candidate For A Potential Buyout In 2021

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia's management team will host a conference call to discuss the Company's financial results and to provide a general business update. The conference call and webcast is scheduled for February 24, 2021 at 4:30pm ET. In order to p

Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021

Lupkynis is the first FDA-approved oral therapy for lupus nephritis. Approved label supports patented dosing protocol, which will last until 2037.

Aurinia Pharmaceuticals' Lupkynis Is Approved - 120%+ Potential Upside In 5 Years

In the following, I review the recent FDA approval and label for LUPKYNIS and tease out some of the bullish implications. I then consider more factors in the comparison to competitor drug Benlysta.

Aurinia Pharmaceuticals Is A Better Value Today At $17 Than It Was A Month Ago At $14

Approval of a new lupus treatment has investors buzzing around this biotech stock.

Here's Why Everybody's Talking About Aurinia Pharmaceuticals Stock

The FDA approved the drugmaker's closely watched lupus nephritis therapy.

Why Aurinia Pharmaceuticals Stock Is Flying Today

AstraZeneca

Constellation Pharmaceuticals Inc

Regeneron Pharmaceuticals

AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister also said he expects the EU to approve the company's COVID-19 vaccine on Friday.

Why Aurinia Pharma, AstraZeneca And More Are Trading Higher Today

Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.

Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes irreversible kidney damage and significantly increases the

FDA Approves Aurinia Pharmaceuticals' LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissioner: H.C. Wainwright Virtual BioConnect 2021 Conference. On-demand fireside chat available beginning Monday, January 11, 2021 at 6:00 a.m. EST; Scott Gottlieb, M.D. Hosts a Panel Di

News for Aurinia Pharmaceuticals Stock (AUPH)